NewAmsterdam Pharma BV, a biotechnology company that aims to treat metabolic diseases, is in talks to go public through a merger with blank-check firm Frazier Lifesciences Acquisition, Bloomberg reports, citing people with knowledge of the matter.
Frazier, a Seattle-based SPAC led by Chairman and Chief Executive Officer Jamie Topper, is in final discussions with investors for a PIPE to support a transaction that’s set to value the combined entity at $700 million.
The SPAC raised $138 million in a December 2020 IPO. Read more.
